Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2024 | CABONEN: cabozantinib in advanced G3 neuroendocrine neoplasia

Rocio Garcia-Carbonero • 18 Sep 2024

ESMO 2024

Neuroendocrine Tumor Cabozantinib

CABONEN

Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, gives an overview of the Phase II CABONEN trial (NCT04524208), which evaluates cabozantinib in patients with G3 neuroendocrine neoplasia (NEN). Preliminary results show a promising 6-month disease control rate, and manageable toxicities. The findings suggest that cabozantinib offers a promising treatment option for patients with low proliferative NEN G3, where therapeutic options are limited. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.